Thought we should circle back around to this and review were we are.
1-3. Generate revenue via worldwide psoriasis cream sales, posting sales figures for Q2, Q3, and Q4.
Looks like a slow launch with possible revenue from a couple EU nations and possibly Canada starting in Q3 but likely extending into Q1 2018 for Canada at the speed we move.
4. Seek fast-track approval for testing cream on other skin ailments, such as eczema, rosacea, seborrheic dermatitis, and acne (?). With safety testing already completed on the formulation for psoriasis, approval for testing for other skin conditions should be expeditious. Approval for alternate use trials by Q3 seems plausible to me.
Working on completing safety trials and should be done soon. Expecting plan to expand study to other conditions any day. Likely won't have efficacy study until Q4 and approval until end of Q1 2018.
5. With money coming in from cream sales, have OWCP retain a top IP law firm such as Ropes & Gray or MoFo to assist with patent protection and licensing agreements.
Looks like we have seem more progress with the MM product than the cream product. My guess is that we are close to an approval for the MM product in Q3... still don't know about cream product as there has been no updates from patent office.
6. Secure additional financing to accelerate the pace of sublingual treatment trials. With revenue coming in, secure a line of credit or seek an investment from a private equity firm. Just like having Emilia Cosmetics and Medmar putting up $300,000 each was a vote of confidence in OWCP, having JPM issue a $10 Million line of credit or having a private equity firm like Apollo taking a small stake would put OWCP in league with big board biotech companies.
Likely possible from listing on TSX... I would expect to see something no later than end of Q3.
7. Uplist. Once OWCP is trading steadily over $1, seek counsel to uplist.
This would be nice but don't know if this will happen in 2017 now. If we can execute the above timely there is a chance for very end of 2017 or early 2018.
8. License sublingual tablet to other biotech companies. Success begets success. Once OWCP is better known, expect companies to come out of the woodworks and pay licensing fees for the sublingual tablet. With each successful deal inked, a press release of “Company X is please to announce it has entered into an agreement with OWC Pharmaceuticals to license OWCP’s sublingual tablet technology, which Company X will use in clinical studies for it’s trails of XYZ to treat [disease]. Company X CEO blah blah said, “We are so excited to license OWCP’s delivery mechanisms as it allows very precise control of dosing. Inhaling cannabis in a doctors office is crude and unscientific…” will be a monthly occurrence.
This seems to have been completely paused. Not sure there is anything coming and dont' see an IP listed for the tablet anymore.
9. Gain approval for multiple myeloma trials in humans.
Expect this will occur sometime Q4.
10. Gain approval for study of formulation to treat fibromyalgia in humans.
2018 - other companies active in this area
11. Gain approval for study of formulation to treat PTSD in humans.
2018- other companies active in this area
12. Gain approval for study of formulation to treat migraine in humans.
2018- other companies active in this area
1-3. Generate revenue via worldwide psoriasis cream sales, posting sales figures for Q2, Q3, and Q4.
Looks like a slow launch with possible revenue from a couple EU nations and possibly Canada starting in Q3 but likely extending into Q1 2018 for Canada at the speed we move.
4. Seek fast-track approval for testing cream on other skin ailments, such as eczema, rosacea, seborrheic dermatitis, and acne (?). With safety testing already completed on the formulation for psoriasis, approval for testing for other skin conditions should be expeditious. Approval for alternate use trials by Q3 seems plausible to me.
Working on completing safety trials and should be done soon. Expecting plan to expand study to other conditions any day. Likely won't have efficacy study until Q4 and approval until end of Q1 2018.
5. With money coming in from cream sales, have OWCP retain a top IP law firm such as Ropes & Gray or MoFo to assist with patent protection and licensing agreements.
Looks like we have seem more progress with the MM product than the cream product. My guess is that we are close to an approval for the MM product in Q3... still don't know about cream product as there has been no updates from patent office.
6. Secure additional financing to accelerate the pace of sublingual treatment trials. With revenue coming in, secure a line of credit or seek an investment from a private equity firm. Just like having Emilia Cosmetics and Medmar putting up $300,000 each was a vote of confidence in OWCP, having JPM issue a $10 Million line of credit or having a private equity firm like Apollo taking a small stake would put OWCP in league with big board biotech companies.
Likely possible from listing on TSX... I would expect to see something no later than end of Q3.
7. Uplist. Once OWCP is trading steadily over $1, seek counsel to uplist.
This would be nice but don't know if this will happen in 2017 now. If we can execute the above timely there is a chance for very end of 2017 or early 2018.
8. License sublingual tablet to other biotech companies. Success begets success. Once OWCP is better known, expect companies to come out of the woodworks and pay licensing fees for the sublingual tablet. With each successful deal inked, a press release of “Company X is please to announce it has entered into an agreement with OWC Pharmaceuticals to license OWCP’s sublingual tablet technology, which Company X will use in clinical studies for it’s trails of XYZ to treat [disease]. Company X CEO blah blah said, “We are so excited to license OWCP’s delivery mechanisms as it allows very precise control of dosing. Inhaling cannabis in a doctors office is crude and unscientific…” will be a monthly occurrence.
This seems to have been completely paused. Not sure there is anything coming and dont' see an IP listed for the tablet anymore.
9. Gain approval for multiple myeloma trials in humans.
Expect this will occur sometime Q4.
10. Gain approval for study of formulation to treat fibromyalgia in humans.
2018 - other companies active in this area
11. Gain approval for study of formulation to treat PTSD in humans.
2018- other companies active in this area
12. Gain approval for study of formulation to treat migraine in humans.
2018- other companies active in this area
2
